AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland....
+See More2018-02-23 09:35:00 Friday ET
Warren Buffett releases his annual letter to Berkshire Hathaway shareholders as of February 2018. Buffett discusses Berkshire's core cash ambition, its
2024-03-26 09:30:00 Tuesday ET
Stock Synopsis: ESG value and momentum stock market portfolio strategies Since 2013, we have been delving into the broad topics of ESG (Environmental, So
2022-11-25 09:29:00 Friday ET
Uniform field theory of corporate finance While the agency and precautionary-motive stories are complementary, these stories can be nested as special cas
2025-07-01 13:35:00 Tuesday ET
In recent times, financial deglobalization and asset market fragmentation can cause profound public policy implications for trade, finance, and technology w
2017-01-23 09:30:00 Monday ET
There are several highlights from the first news conference after Trump's presidential election victory: The Trump administration will repeal-and-
2019-07-17 12:37:00 Wednesday ET
Gold prices surge above $1400 per ounce amid global trade tension and economic policy uncertainty. Both European Central Bank and Bank of Japan may consider